{{Drugbox
| verifiedrevid = 448228579
| IUPAC_name = (3aα,4α,4aβ,6aβ,7α,7aα)-Hexahydro-2-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)-4,7-etheno-1''H''-cyclobut[''f'']isoindole-1,3(2''H'')-dione
| image = Zalospirone.svg

<!--Clinical data-->
| tradename =  
| pregnancy_category =  
| legal_status = Uncontrolled
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability =  
| metabolism =  
| elimination_half-life = 1-4 hours
| excretion =  

<!--Identifiers-->
| CAS_number = 114298-18-9
| ATC_prefix = none
| ATC_suffix =  
| PubChem = 163925
|  ChemSpiderID = 143768
| IUPHAR_ligand = 58
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 0449O95Z1J

<!--Chemical data-->
| C=24 | H=29 | N=5 | O=2 
| molecular_weight = 419.519 g/mol
| smiles            = O=C1N(C(=O)[C@@H]4[C@H]1[C@@H]2\C=C/[C@H]4[C@H]3\C=C/[C@@H]23)CCCCN6CCN(c5ncccn5)CC6
| StdInChI          = 1S/C24H29N5O2/c30-22-20-18-6-7-19(17-5-4-16(17)18)21(20)23(31)29(22)11-2-1-10-27-12-14-28(15-13-27)24-25-8-3-9-26-24/h3-9,16-21H,1-2,10-15H2/t16-,17+,18-,19+,20-,21+
| StdInChIKey       = AERLHOTUXIJQFV-RCPZPFRWSA-N
}}

'''Zalospirone''' ('''WY-47,846''') is a [[binding_selectivity|selective]] [[5-HT1A receptor|5-HT<sub>1A</sub>]] [[partial agonist]] of the [[azapirone]] [[chemical class]].<ref>{{cite journal | last1 = Gleeson | first1 = S | last2 = Barrett | first2 = JE | title = 5-HT1A agonist effects on punished responding of squirrel monkeys | journal = Pharmacology, Biochemistry, and Behavior | volume = 37 | issue = 2 | pages = 335–7 | year = 1990 | pmid = 1981937 | doi=10.1016/0091-3057(90)90344-H}}</ref><ref>{{cite journal | last1 = Singh | first1 = A | last2 = Lucki | first2 = I | title = Antidepressant-like activity of compounds with varying efficacy at 5-HT1A receptors | journal = Neuropharmacology | volume = 32 | issue = 4 | pages = 331–40 | year = 1993 | pmid = 8497336 | doi=10.1016/0028-3908(93)90153-T}}</ref> It was found to be effective in the treatment of [[anxiety]] and [[major depressive disorder|depression]] in [[clinical trial]]s, but a high proportion of subjects dropped out due to [[side effect]]s and development was subsequently never completed.<ref>{{cite journal | last1 = Rickels | first1 = K | last2 = Derivan | first2 = A | last3 = Kunz | first3 = N | last4 = Pallay | first4 = A | last5 = Schweizer | first5 = E | title = Zalospirone in major depression: a placebo-controlled multicenter study | journal = Journal of Clinical Psychopharmacology | volume = 16 | issue = 3 | pages = 212–7 | year = 1996 | pmid = 8784652 | doi = 10.1097/00004714-199606000-00004 }}</ref>

== See also ==
* [[Azapirone]]

== References ==
{{Reflist|2}}


{{Anxiolytics}}
{{Antidepressants}}
{{Serotonergics}}
{{Piperazines}}

[[Category:Piperazines]]
[[Category:Pyrimidines]]
[[Category:Imides]]
[[Category:Azapirones]]
[[Category:Cyclobutenes]]

{{nervous-system-drug-stub}}